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Abstract 
 
We previously reported that intracerebroventricularly (i.c.v.) administered 
corticotropin-releasing factor (CRF) (0.5-3.0 nmol/animal) dose-dependently elevates 
plasma noradrenaline and adrenaline through brain phospholipase C-, diacylglycerol 
lipase- and prostanoids-mediated mechanisms in rats. Diacylglycerol produced by 
phospholipase C from phospholipids can be hydrolyzed by diacylglycerol lipase into 2-
arachidonoylglycerol, which may be further hydrolyzed by monoacylglycerol lipase 
into arachidonic acid, a precursor of prostanoids. Recently, 2-arachidonoylglycerol has 
been recognized as a major brain endocannabinoid, which can modulate synaptic 
transmission through presynaptic cannabinoid CB1 receptors. Released 2-
arachidonoylglycerol is rapidly deactivated by uptake into cells and enzymatic 
hydrolysis. In the present study, therefore, we examined (1) the involvement of brain 2-
arachidonoylglycerol, (2) the regulatory role of 2-arachidonoylglycerol as a brain 
endocannabinoid, and (3) the effect of exogenous cannabinoid receptor agonist, on the 
CRF-induced elevation of plasma noradrenaline and adrenaline using anesthetized rats. 
The elevation of both catecholamines induced by a submaximal dose of CRF (1.5 
nmol/animal, i.c.v.) was reduced by i.c.v. administered MAFP (monoacylglycerol 
lipase inhibitor) (0.7 and 1.4 µmol/animal), AM 404 (endocannabinoid uptake-
inhibitor) (80 and 250 nmol/animal) and ACEA (cannabinoid CB1 receptor agonist) 
(0.7 and 1.4 µmol/animal, i.c.v.), while AM 251 (cannabinoid CB1 receptor antagonist) 
(90 and 180 nmol/animal, i.c.v.) potentiated the response induced by a small dose of 
CRF (0.5 nmol/animal, i.c.v.). These results suggest a possibility that 2-
arachidonoylglycerol is endogenously generated in the brain during CRF-induced 
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activation of central sympatho-adrenomedullary outflow, thereby inhibiting the 
peptide-induced response by activation of brain cannabinoid CB1 receptors in 
anesthetized rats. 
 
 
 
Keywords:  Corticotropin-releasing factor; Sympatho-adrenomedullary outflow; 
Brain; 2-Arachidonoylglycerol; Monoacylglycerol lipase; Cannabinoid CB1 receptor 
 
 
4 
1.  Introduction 
 
The endogenous cannabinoids that have received the most experimental attention 
are the arachidonic acid-containing lipids known as anandamide and 2-
arachidonylglycerol. 2-Arachidonoylglycerol has been recognized as a major brain 
endocannabinoid because it acts as a full agonist at cannabinoid CB receptors while 
anandamide acts as a partial agonist (Sugiura and Waku, 2000) and 2-
arachidonoylglycerol is several 100-fold more abundant than anandamide in the brain 
(Stella et al., 1997; Sugiura and Waku, 2000). 2-Arachidonoylglycerol produced on 
demand from membrane phospholipid of postsynaptic neurons acts on presynaptic 
cannabinoid CB1 receptors, thereby inhibiting the release of neurotransmitters (Stella 
et al., 1997; Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001; Freund et al., 
2003). The released 2-arachidonoylglycerol into the synaptic cleft is considered to be 
rapidly inactivated by uptake into neurons (Di Marzo, 2006; Centonze et al., 2007; 
Bisogno, 2008). The 2-arachidonoylglycerol-induced retrograde signaling process 
seems to be involved in the widespread central effects including synaptic plasticity 
(Heifets and Castillo, 2009), neuroprotection (Centonze et al., 2007), epilepsy 
(Ludányi et al., 2008), depression (Vinod and Hungund, 2006), food intake (Di Marzo 
et al., 2009), and also in the baroreflex-evoked central sympathetic modulation 
(Brozoski et al., 2005).  
2-Arachidonoylglycerol is generated from diacylglycerol, which is produced by 
hydrolysis of arachidonic acid-enriched membrane phospholipids through 
phospholipase C (Stella et al., 1997; Di Marzo, 2006; Tang et al., 2006; Bisogno, 
2008). Diacylglycerol containing arachidonic acid in position 2 is hydrolyzed to 2-
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arachidonoylglycerol by sn-1 selective diacylglycerol lipase (Stella et al., 1997; 
Bisogno et al., 2003; Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008). Actually, 
overexpression of the lipase in mouse neuroblastoma increases basal 2-
arachidonoylglycerol levels (Jung et al., 2007). 2-Arachidonoylglycerol can be further 
hydrolyzed by monoacylglycerol lipase to generate arachidonic acid and glycerol (Dinh 
et al., 2002; Di Marzo, 2006; Tang et al., 2006; Bisogno, 2008). Recently, we reported 
the involvement of brain arachidonic acid generated by brain phospholipase C-, 
diacylglycerol lipase- and monoacylglycerol lipase-mediated mechanisms in centrally 
administered arginine-vasopressin-induced elevation of plasma noradrenaline and 
adrenaline in rats (Shimizu et al., 2004; Shimizu and Yokotani, 2008). Brain 
arachidonic acid has already been shown to be involved as a precursor of prostanoids 
in this peptide-induced elevation of plasma catecholamines (Yokotani et al., 1995, 
2000; Murakami et al., 2002; Okada et al., 2003a). Furthermore, it is interesting to note 
that 2-arachidonoylglycerol, a precursor of arachidonic acid, plays a modulating role as 
an endocannabinoid to inhibit the arginine-vasopressin-induced response (Shimizu and 
Yokotani, 2008).  
Previously, we also reported that brain phospholipase C, diacylglycerol lipase 
and prostanoids are involved in the centrally administered corticotropin-releasing 
factor (CRF)-induced elevation of plasma noradrenaline and adrenaline in rats 
(Yokotani et al., 2001; Okada et al., 2003b). Therefore we propose, on the basis of 
recent studies in our laboratory, to examine (1) the involvement of brain 2-
arachidonoylglycerol in the CRF-induced response. Furthermore, we examined (2) the 
regulatory role of 2-arachidonoylglycerol as a brain endocannabinoid, and (3) the effect 
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of centrally administered cannabinoid receptor agonist on the CRF-induced response, 
in anesthetized rats. 
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2.  Materials and methods 
    
2.1.  Experimental procedures 
 
All experiments were conducted in compliance with the guiding principles for 
the care and use of laboratory animals approved by Kochi University, which are in 
accordance with the “Guidelines for proper conduct of animal experiments” from the 
Science Council of Japan. Male Wistar rats weighing about 350 g were maintained in 
an air-conditioned room at 22-24°C under a constant day-night rhythm for more than 2 
weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and 
water ad libitum. In the morning (09:00~10:00), the femoral vein was cannulated for 
infusion of saline (1.2 ml/h) and the femoral artery was cannulated for collecting blood 
samples, under urethane anesthesia (1.2 g/kg, i.p.). After these procedures, the animal 
was placed in a stereotaxic apparatus until the end of each experiment, as shown in our 
previous papers (Yokotani et al., 1995; Shimizu et al., 2004). The skull was drilled for 
intracerebroventricular administration of test substances using a stainless-steel cannula 
(0.3 mm outer diameter). The stereotaxic coordinates of the tip of the cannula were as 
follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from 
the midline; V, below the surface of the brain), according to the rat brain atlas (Paxinos 
and Watson, 2005). Three hours were allowed to elapse before the application of 
reagents. 
MAFP (a monoacylglycerol lipase inhibitor), AM 251 (a cannabinoid CB1 
receptor antagonist), AM 404 (an uptake-inhibitor of endocannabinoid) and ACEA (a 
cannabinoid CB1 receptor agonist) dissolved in 3 µl of 100% N,N-dimethylformamide 
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(DMF)/animal were intracerebroventricularly (i.c.v.) administered using the cannula 
connected to a 10-µl Hamilton syringe, which was retained for 15 min to avoid the 
leakage of these reagents and then removed from the ventricle. CRF dissolved in sterile 
saline in a volume of 10 µl/animal was then slowly administered into the ventricle, 30 
min after application of MAFP, AM 251 and ACEA and 60 min after application of 
AM 404, due to their slightly elevating effects on the basal plasma levels of 
catecholamines, using the same cannula connected to a 25-µl Hamilton syringe. The 
cannula was retained until the end of the experiment. 
 
2.2.  Measurement of plasma catecholamines 
 
Blood samples (250 µl) were collected through an arterial catheter and were 
preserved on ice during experiments. Plasma was prepared immediately after the final 
sampling. Catecholamines in the plasma were extracted by the method of Anton and 
Sayre (1962) with a slight modification and were assayed electrochemically with high 
performance liquid chromatography (HPLC) (Shimizu et al., 2004). Briefly, after 
centrifugation (1,500 g for 10 min, at 4°C), the plasma (100 µl) was transferred to a 
centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 
1 ml of 1.5 M Tris buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-
dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the 
alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, 
catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid 
containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a 
sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical 
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detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. 
Analytical conditions were as follows: detector, +450 mV potential against an 
Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); 
mobile phase, 0.1 M NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium 
EDTA, 0.75 g/l sodium 1-octanesulfonate and 15% methanol at a flow rate of 0.18 
ml/min; injection volume, 40 µl. The amount of catecholamines in each sample was 
calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By 
this assay, coefficients of variation for the intra- and inter-assay were 3.0 and 3.7%, 
respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined. 
 
2.3.  Treatment of data and statistics  
  
Increments of plasma catecholamines above the basal level at each time are 
expressed as pg/ml. The area under the curve (AUC) is also expressed as pg/2 h. The 
number of animals in each group is shown in all figures. All values are expressed as 
the mean±S.E.M. Statistical differences are determined using repeated-measure 
(treatment × time) or one-way analysis of variance (ANOVA), followed by post-hoc 
analysis with the Bonferroni method. P values less than 0.05 were taken to indicate 
statistical significance. 
 
2.4.  Compounds 
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The following drugs were used: synthetic CRF (rat/human) (Peptide Institute, 
Osaka, Japan); MAFP (methyl arachidonoyl fluorophosphonate), AM 251 [N-
(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide], AM 404 [N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetrenamide] and 
ACEA (arachidonyl 2’-chloroethylamide) (Cayman Chemical, Ann Arbor, MI, U.S.A.). 
All other reagents were of the highest grade available (Nacalai Tesque, Kyoto, Japan). 
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3.  Results 
 
3.1.  Effect of MAFP on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines  
 
Repeated-measure ANOVA showed for plasma levels of catecholamines 
(noradrenaline and adrenaline) significant effects of treatment [noradrenaline, 
F(4,18)=26.42, P<0.05; adrenaline, F(4,18)=53.34, P<0.05], time [noradrenaline, 
F(4,69)=28.97, P<0.05; adrenaline, F(4,68)=48.07, P<0.05] and the interaction 
between these two factors [noradrenaline, F(16,69)=11.31, P<0.05; adrenaline, 
F(16,68)=13.21, P<0.05] (Fig. 1A). One-way ANOVA also revealed significant effects 
of treatment on plasma catecholamines [noradrenaline, F(4,17)=26.39, P<0.05; 
adrenaline, F(4,18)=74.24, P<0.05] (Fig. 1B). 
Treatments with vehicle-1 (3 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl 
saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and 
adrenaline (Fig. 1, A and B). Pretreatment with MAFP (an inhibitor of 
monoacylglycerol lipase) [1.4 µmol (500 µg)/animal, i.c.v.] had a slight, but significant 
inhibitory effect on the basal plasma noradrenaline level, but had no significant effect 
on the basal plasma adrenaline level (Fig. 1, A and B).  
Since we previously reported that CRF (0.5, 1.5 and 3.0 nmol/animal, i.c.v.) 
dose-dependently elevated plasma levels of noradrenaline and adrenaline (Yokotani et 
al., 2001), we used a sub-maximum dose of 1.5 nmol/animal in the present study. 
Administration of CRF (1.5 nmol/animal, i.c.v.) gradually elevated the plasma levels 
of noradrenaline and adrenaline and the responses reached a maximum 90 min after the 
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administration of this peptide (Fig. 1A). The CRF-induced elevation of both 
catecholamines was reduced by MAFP in a dose-dependent manner [0.7 and 1.4 µmol 
(250 and 500 µg)/animal, i.c.v.] (Fig. 1, A and B). 
 
3.2.  Effect of AM 251 on the centrally administered CRF (0.5 nmol/animal)-induced 
elevation of plasma catecholamines 
 
Repeated-measure ANOVA showed for plasma levels of catecholamines 
(noradrenaline and adrenaline) significant effects of treatment [noradrenaline, 
F(4,20)=21.85, P<0.05; adrenaline, F(4,20)=30.04, P<0.05], time [noradrenaline, 
F(4,79)=14.89, P<0.05; adrenaline, F(4,74)=11.81, P<0.05] and the interaction 
between these two factors [noradrenaline, F(16,79)=7.37, P<0.05; adrenaline, 
F(16,74)=4.73, P<0.05] (Fig. 2A). One-way ANOVA also revealed significant effects 
of treatment on plasma catecholamines [noradrenaline, F(4,20)=21.09, P<0.05; 
adrenaline, F(4,19)=27.78, P<0.05] (Fig. 2B). 
Pretreatment with AM 251 (a selective antagonist of cannabinoid CB1 receptors) 
[180 nmol (100 µg)/animal, i.c.v.] had no significant effect on the basal plasma levels 
of both catecholamines (Fig. 2, A and B). 
In this experiment, we used a small dose of CRF (0.5 nmol/animal, i.c.v.) to 
clarify the potentiating effect of cannabinoid CB1 receptor antagonist on plasma 
catecholamines induced by this peptide. Administration of CRF (0.5 nmol/animal, 
i.c.v.) slightly, but significantly elevated plasma levels of noradrenaline and adrenaline 
during 120 min after the administration of this peptide (Fig. 2A). The CRF-induced 
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elevation of both catecholamines was potentiated by AM 251 in a dose-dependent 
manner [90 and 180 nmol (50 and 100 µg)/animal, i.c.v.] (Fig. 2, A and B). 
 
3.3.  Effect of AM 404 on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines  
 
Repeated-measure ANOVA showed for plasma levels of catecholamines 
(noradrenaline and adrenaline) significant effects of treatment [noradrenaline, 
F(4,21)=27.24, P<0.05; adrenaline, F(4,21)=24.18, P<0.05], time [noradrenaline, 
F(4,82)=75.33, P<0.05; adrenaline, F(4,81)=38.22, P<0.05] and the interaction 
between these two factors [noradrenaline, F(16,82)=12.65, P<0.05; adrenaline, 
F(16,81)=7.81, P<0.05] (Fig. 3A). One-way ANOVA also revealed significant effects 
of treatment on plasma catecholamines [noradrenaline, F(4,21)=25.86, P<0.05; 
adrenaline, F(4,21)=23.18, P<0.05] (Fig. 3B). 
Treatments with vehicle-1 (3 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl 
saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and 
adrenaline (Fig. 3, A and B). Pretreatment with AM 404 (an uptake-inhibitor of 
endocannabinoid) [250 nmol (100 µg)/animal, i.c.v.] had no significant effect on the 
basal plasma levels of both catecholamines (Fig. 3, A and B). 
The CRF (1.5 nmol/animal, i.c.v.)-induced elevation of plasma noradrenaline 
and adrenaline was reduced by AM 404 in a dose-dependent manner [80 and 250 nmol 
(30 and 100 µg)/animal, i.c.v.] (Fig. 3, A and B). 
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3.4.  Effect of ACEA on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines 
 
Repeated-measure ANOVA showed for plasma levels of catecholamines 
(noradrenaline and adrenaline) significant effects of treatment [noradrenaline, 
F(4,17)=33.66, P<0.05; adrenaline, F(4,17)=18.45, P<0.05], time [noradrenaline, 
F(4,67)=42.99, P<0.05; adrenaline, F(4,64)=23.94, P<0.05] and the interaction 
between these two factors [noradrenaline, F(16,67)=9.84, P<0.05; adrenaline, 
F(16,64)=6.58, P<0.05] (Fig. 4A). One-way ANOVA also revealed significant effects 
of treatment on plasma catecholamines [noradrenaline, F(4,17)=31.29, P<0.05; 
adrenaline, F(4,17)=23.40, P<0.05] (Fig. 4B). 
Pretreatment with ACEA (a selective agonist of cannabinoid CB1 receptors) [1.4 
µmol (500 µg)/animal, i.c.v.] had no significant effect on the basal plasma levels of 
both catecholamines (Fig. 4, A and B). 
The CRF (1.5 nmol/animal, i.c.v.)-induced elevation of noradrenaline and 
adrenaline was reduced by ACEA in a dose-dependent manner [0.7 and 1.4 µmol (250 
and 500 µg)/animal, i.c.v.] (Fig. 4, A and B). On the other hand, intravenous 
administration of ACEA (1.4 µmol/animal) had no effect on the CRF-induced response 
(data not shown). 
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4.  Discussion 
 
2-Arachidonoylglycerol generated by phospholipase C and sn-1 selective 
diacylglycerol lipase (Stella et al., 1997; Bisogno et al., 2003; Di Marzo, 2006; Tang et 
al., 2006; Bisogno, 2008) can be hydrolyzed by monoacylglycerol lipase to arachidonic 
acid (Dinh et al., 2002; Di Marzo, 2006; Quistad et al., 2006; Tang et al., 2006; 
Blankman et al., 2007; Bisogno, 2008). In addition, arachidonic acid can be also 
produced from diacylglycerol containing the fatty acid in position 2 by sn-2 selective 
diacylglycerol lipase (Bell et al., 1979). Brain phospholipase C, diacylglycerol lipase 
and prostanoids, active metabolites of arachidonic acid, have been shown to be 
involved in the centrally administered CRF-induced elevation of plasma noradrenaline 
and adrenaline (Yokotani et al., 2001; Okada et al., 2003b). Therefore, we examined 
whether 2-arachidonoylglycerol is involved as a precursor of arachidonic acid in the 
CRF-induced response using MAFP. This reagent is currently recognized as a very 
potent inhibitor of 2-arachidonoylglycerol hydrolyzing enzymatic activity with an IC50 
value of 2-3 nM (Goparaju et al., 1999; Saario et al., 2004) and actually accumulates 
endogenous 2-arachidonoylglycerol in rat brain sections (Palomäki et al., 2007). 
Previously we also reported that centrally administered MAFP also reduced the 
elevation of plasma catecholamines induced by centrally administered 2-
arachidonoylglycerol (Shimizu and Yokotani, 2008). In the present experiment, 
centrally administered MAFP effectively reduced the CRF-induced elevation of plasma 
catecholamines, suggesting the involvement of brain 2-arachidonoylglycerol generated 
by sn-1 selective diacylglycerol lipase in the CRF-induced activation of central 
sympatho-adrenomedullary outflow in rats.  
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Recently, 2-arachidonoylglycerol has been recognized as a major endogenous 
ligand for two cannabinoid receptors, CB1 and CB2 (Matsuda et al., 1990; Munro et al., 
1993). Cannabinoid CB1 receptors are predominantly expressed in the central nervous 
system, whereas cannabinoid CB2 receptors are present mainly in the immune system 
(Howlett et al., 2002; Mackie, 2008). Brain 2-arachidonoylglycerol has been shown to 
inhibit neurotransmission through presynaptic cannabinoid CB1 receptors (Ohno-
Shosaku et al., 2001; Freund et al., 2003) and we recently reported that brain 
cannabinoid CB1 receptors, but not cannabinoid CB2 receptors, play an inhibitory role 
in the centrally administered arginine-vasopressin-induced elevation of plasma 
catecholamines (Shimizu and Yokotani, 2008). Therefore we examined whether the 
endogenously generated 2-arachidonoylglycerol has an inhibitory role as an 
endocannabinoid in the centrally administered CRF-induced elevation of plasma 
catecholamines with regard to cannabinoid CB1 receptors. In the present experiment, 
we used a selective cannabinoid CB1 receptor antagonist AM 251 (Lan et al., 1999), 
which actually reverses the orexigenic effect induced by 2-arachidonoylglycerol 
administered into pontine parabrachial nucleus in rats (DiPatrizio and Simansky, 2008) 
and the protective effect against brain ischemia caused by electroacupuncture-induced 
elevation of brain 2-arachidonoylglycerol content in rats (Wang et al., 2009). Centrally 
pretreated AM 251 effectively potentiated the elevation of plasma catecholamines 
induced by a small dose of CRF, suggesting a possibility that endogenously generated 
2-arachidonoylglycerol has an inhibitory effect on the CRF-induced activation of 
central sympatho-adrenomedullary outflow through cannabinoid CB1 receptors in rats. 
The released 2-arachidonoylglycerol into the synaptic cleft in the brain seems to 
be rapidly uptaken into neurons and degraded for termination of the endocannabinoid 
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signaling (Di Marzo, 2006; Centonze et al., 2007; Bisogno, 2008). The uptake is 
considered to occur through a plasma membrane transporter that has not been isolated 
or cloned yet (Bisogno, 2008). Several reagents, including AM 404, have been shown 
to inhibit the cellular uptake of 2-arachidonoylglycerol (Centonze et al., 2007). AM 
404 was originally reported as an inhibitor of anandamide transport (Beltramo et al., 
1997), and this reagent actually induces anandamide accumulation in the rat brain 
(Giuffrida et al., 2001) and increases an activity-dependent anandamide level in rat 
hypothalamic slices (Di et al., 2005). Interestingly, AM 404 also elicits an activity-
dependent increase of 2-arachidonoylglycerol in rat hypothalamic slices (Di et al., 
2005) and inhibits the uptake of 2-arachidonoylglycerol in C6 glioma cells (Bisogno et 
al., 2001). In the present experiment, central pretreatment with AM 404 effectively 
reduced the centrally administered CRF-induced elevation of plasma catecholamines, 
suggesting a possibility that AM 404-induced synaptic accumulation of endogenously 
generated brain 2-arachidonoylglycerol negatively modulates the CRF-induced 
activation of central sympatho-adrenomedullary outflow in rats. 
In the next experiment, we examined the effect of exogenously administered 
ACEA, a selective agonist of cannabinoid CB1 receptors (Hillard et al., 1999), on the 
centrally administered CRF-induced elevation of plasma catecholamines. This agonist 
administered into the dorsolateral periaqueductal gray induces an anxiolytic effect in 
rats and centrally administered this reagent decreases the frequency of epileptiform 
activity in epilepsy model rats (Moreira et al., 2007; Kozan et al., 2009). In the present 
experiment, centrally administered ACEA effectively reduced the CRF-induced 
elevation of plasma catecholamines, but peripherally administered ACEA had no effect. 
The result indicates that exogenously administered cannabinoid CB1 receptor agonist 
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into the brain further inhibits the CRF-induced activation of central sympatho-
adrenomedullary outflow in addition to the inhibition induced by CRF-induced 
endogenously generated brain 2-arachidonoylglycerol. 
Centrally administered cannabinoid CB1 receptor agonists can inhibit the 
activation of central sympatho-adrenomedullary outflow. However, one of the major 
drawbacks of the use of agonists is that cannabinoid CB1 receptors have a widespread 
distribution in the brain (Howlett et al., 2002; Mackie, 2008) and global activation of 
these receptors is associated with adverse side effects such as sedation, dependence, 
cognitive impairment and psychosis (Kalant, 2004; Pacher et al., 2006). On the other 
hand, endocannabinoid uptake-inhibitors can elevate the synaptic content of 
endocannabinoid at sites of high endocannabinoid turnover. From our studies, brain 2-
arachidonoylglycerol can be endogenously generated during the CRF-induced 
activation of central sympatho-adrenomedullary outflow and the activation was 
effectively inhibited by centrally administered AM 404 (an uptake-inhibitor of 
endocannabinoid). Furthermore, Brozoski et al. reported that AM 404 administered in 
the nucleus tractus solitarius after an increase in blood pressure prolongs baroreflex 
inhibition of renal sympathetic nerve activity in rats (Brozoski et al., 2005). These lines 
of evidence suggest a possibility that endocannabinoid uptake-inhibitors can locally 
activate cannabinoid CB1 receptors at sites of high endocannabinoid turnover and 
inhibit the activation of central sympatho-adrenomedullary outflow. Taken together, it 
is suggested that endocannabinoid uptake-inhibitors rather than agonists of 
cannabinoid CB1 receptors are beneficial targets for therapeutic drugs to inhibit central 
sympatho-adrenomedullary outflow without adverse side effects on other brain 
functions.     
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In summary, it seems likely that brain 2-arachidonoylglycerol is endogenously 
generated during the centrally administered CRF-induced activation of sympatho-
adrenomedullary outflow, thereby inhibiting the peptide-induced response by brain 
cannabinoid CB1 receptor-mediated mechanisms in anesthetized rats. 
 
20 
Acknowledgments 
 
    The authors thank K. Nakamura for technical assistance (measurement of plasma 
noradrenaline and adrenaline). This work was supported in part by a Grant-in-Aid for 
Young Scientists (B) (No. 21790627 to T.S.) from The Ministry of Education, Culture, 
Sports, Science and Technology, a Grant-in-Aid for Scientific Research (C) (No. 
20590702 to K.Y.) from the Japan Society for the Promotion of Science, a Grant from 
The Smoking Research Foundation in Japan, a Discretionary Grant of the Head of the 
Kochi Medical School Hospital, and specific Research Grants from Kochi University.
21 
References 
 
Anton, A.H., Sayre, D.F., 1962. A study of the factors affecting the aluminum oxide-
trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. 
Ther. 138, 360-375. 
Bell, R.L., Kennerly, D.A., Stanford, N., Majerus, P.W., 1979. Diglyceride lipase: a 
pathway for arachidonate release from human platelets. Proc. Natl. Acad. Sci. 
U.S.A. 76, 3238-3241. 
Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D., 1997. 
Functional role of high-affinity anandamide transport, as revealed by selective 
inhibition. Science 277, 1094-1097. 
Bisogno, T., MacCarrone, M., De Petrocellis, L., Jarrahian, A., Finazzi-Agrò, A., 
Hillard, C., Di Marzo, V., 2001. The uptake by cells of 2-arachidonoylglycerol, an 
endogenous agonist of cannabinoid receptors. Eur. J. Biochem. 268, 1982-1989. 
Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M.G., Ligresti, A., Matias, I., 
Schiano-Moriello, A., Paul, P., Williams, E.J., Gangadharan, U., Hobbs, C., Di 
Marzo, V., Doherty, P., 2003. Cloning of the first sn1-DAG lipases points to the 
spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell 
Biol. 163, 463-468. 
Bisogno, T., 2008. Endogenous cannabinoids: structure and metabolism. J. 
Neuroendocrinol. 20, 1-9. 
Blankman, J.L., Simon, G.M., Cravatt, B.F., 2007. A comprehensive profile of brain 
enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 
14, 1347-1356. 
22 
Brozoski, D.T., Dean, C., Hopp, F.A., Seagard, J.L., 2005. Uptake blockade of 
endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition. 
Brain Res. 1059, 197-202. 
Centonze, D., Finazzi-Agrò, A., Bernardi, G., Maccarrone, M., 2007. The 
endocannabinoid system in targeting inflammatory neurodegenerative diseases. 
Trends Pharmacol. Sci. 28, 180-187. 
Di, S., Boudaba, C., Popescu, I.R., Weng, F.J., Harris, C., Marcheselli, V.L., Bazan, 
N.G., Tasker, J.G., 2005. Activity-dependent release and actions of 
endocannabinoids in the rat hypothalamic supraoptic nucleus. J. Physiol. 569, 
751-760. 
Di Marzo, V., 2006. A brief history of cannabinoid and endocannabinoid pharmacology 
as inspired by the work of British scientists. Trends Pharmacol. Sci. 27, 134-140. 
Di Marzo, V., Ligresti, A., Cristino, L., 2009. The endocannabinoid system as a link 
between homoeostatic and hedonic pathways involved in energy balance 
regulation. Int. J. Obes. 33, S18-S24.  
Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, 
S., Piomelli, D., 2002. Brain monoglyceride lipase participating in 
endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99, 10819-10824. 
DiPatrizio, N.V., Simansky, K.J., 2008. Activating parabrachial cannabinoid CB1 
receptors selectively stimulates feeding of palatable foods in rats. J. Neurosci. 28, 
9702-9709. 
Freund, T.F., Katona, I., Piomelli, D., 2003. Role of endogenous cannabinoids in 
synaptic signaling. Physiol. Rev. 83, 1017-1066. 
23 
Giuffrida, A., Beltramo, M., Piomelli, D., 2001. Mechanisms of endocannabinoid 
inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298, 7-14. 
Goparaju, S.K., Ueda, N., Taniguchi, K., Yamamoto, S., 1999. Enzymes of porcine 
brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid 
receptors. Biochem. Pharmacol. 57, 417-423. 
Heifets, B.D., Castillo, P.E., 2009. Endocannabinoid signaling and long-term synaptic 
plasticity. Annu. Rev. Physiol. 71, 283-306. 
Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., Ross, R.A., Stevenson, L.A., 
Murphy, V., Pertwee, R.G., Campbell, W.B. 1999. Synthesis and characterization 
of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. 
Pharmacol. Exp. Ther. 1999, 1427-1433. 
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, 
C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G., 
2002. International Union of Pharmacology. XXVII. Classification of cannabinoid 
receptors. Pharmacol. Rev. 54, 161-202. 
Jung, K.M., Astarita, G., Zhu, C., Wallace, M., Mackie, K., Piomelli, D. 2007. A key 
role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent 
endocannabinoid mobilization. Mol. Pharmacol. 72, 612-621. 
Kalant, H., 2004. Adverse effects of cannabis on health: an update of the literature since 
1996. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 849-863. 
Kozan, R., Ayyildiz, M., Agar, E., 2009. The effects of intracerebroventricular AM-251, 
a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-
induced epileptiform activity in rats. Epilepsia 50, 1760-1767. 
24 
Kreitzer, A.C., Regehr, W.G., 2001. Retrograde inhibition of presynaptic calcium influx 
by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 
717-727. 
Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S.R., McCallion, D., Pertwee, R., 
Makriyannis, A., 1999. Structure-activity relationships of pyrazole derivatives as 
cannabinoid receptor antagonists. J. Med. Chem. 42, 769-776. 
Ludányi, A., Eross, L., Czirják, S., Vajda, J., Halász, P., Watanabe, M., Palkovits, M., 
Maglóczky, Z., Freund, T.F., Katona, I., 2008. Downregulation of the CB1 
cannabinoid receptor and related molecular elements of the endocannabinoid 
system in epileptic human hippocampus. J. Neurosci. 28, 2976-2990. 
Mackie, K., 2008. Cannabinoid receptors: where they are and what they do. J. 
Neuroendocrinol. 20, 10-14. 
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I., 1990. 
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. 
Nature 346, 561-564. 
Moreira, F.A., Aguiar, D.C., Guimarães, F.S., 2007. Anxiolytic-like effect of 
cannabinoids injected into the rat dorsolateral periaqueductal gray. 
Neuropharmacology 52, 958-965. 
Munro, S., Thomas, K.L., Abu-Shaar, M., 1993. Molecular characterization of a 
peripheral receptor for cannabinoids. Nature 365, 61-65. 
Murakami, Y., Okada, S., Nishihara, M., Yokotani, K., 2002. Roles of brain 
prostaglandin E2 and thromboxane A2 in the activation of the central sympatho-
adrenomedullary outflow in rats. Eur. J. Pharmacol. 452, 289-294. 
Ohno-Shosaku, T., Maejima, T., Kano, M., 2001. Endogenous cannabinoids mediate 
25 
retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. 
Neuron 29, 729-738. 
Okada, S., Murakami, Y., Yokotani, K., 2003a. Role of brain thromboxane A2 in the 
release of noradrenaline and adrenaline from adrenal medulla in rats. Eur. J. 
Pharmacol. 467, 125-131. 
Okada, S., Shimizu, T., Yokotani, K., 2003b. Brain phospholipase C and diacylglycerol 
lipase are involved in corticotropin-releasing hormone-induced sympatho-
adrenomedullary outflow in rats. Eur. J. Pharmacol. 475, 49-54. 
Pacher, P., Bátkai, S., Kunos, G., 2006. The endocannabinoid system as an emerging 
target of pharmacotherapy. Pharmacol. Rev. 58, 389-462. 
Palomäki, V.A., Lehtonen, M., Savinainen, J.R., Laitinen, J.T., 2007. Visualization of 
2-arachidonoylglycerol accumulation and cannabinoid CB1 receptor activity in rat 
brain cryosections by functional autoradiography. J. Neurochem. 101, 972-981. 
Paxinos, G., Watson, C., 2005. In: Paxinos, G., Watson, C. (Eds.), The Rat Brain in 
Stereotaxic Coordinates. Elsevier Academic Press, Burlington. 
Quistad, G.B., Klintenberg, R., Caboni, P., Liang, S.N., Casida, J.E., 2006. 
Monoacylglycerol lipase inhibition by organophosphorus compounds leads to 
elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. 
Toxicol. Appl. Pharmacol. 211, 78-83. 
Saario, S.M., Savinainen, J.R., Laitinen, J.T., Jarvinen, T., Niemi, R., 2004. 
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-
arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 67, 1381-
1387. 
26 
Shimizu, T., Okada, S., Yamaguchi-Shima, N., Yokotani, K., 2004. Brain 
phospholipase C-diacylglycerol lipase pathway is involved in vasopressin-induced 
release of noradrenaline and adrenaline from adrenal medulla in rats. Eur. J. 
Pharmacol. 499, 99-105.  
Shimizu, T., Yokotani, K., 2008. Bidirectional roles of the brain 2-arachidonoyl-sn-
glycerol in the centrally administered vasopressin-induced adrenomedullary 
outflow in rats. Eur. J. Pharmacol. 582, 62-69. 
Stella, N., Schweitzer, P., Piomelli, D., 1997. A second endogenous cannabinoid that 
modulates long-term potentiation. Nature 388, 773-778. 
Sugiura, T., Waku, K., 2000. 2-Arachidonoylglycerol and the cannabinoid receptors. 
Chem. Phys. Lipids 108, 89-106. 
Tang, X., Edwards, E.M., Holmes, B.B., Falck, J.R., Campbell, W.B., 2006. Role of 
phospholipase C and diacylglyceride lipase pathway in arachidonic acid release 
and acetylcholine-induced vascular relaxation in rabbit aorta. Am. J. Physiol. 
Heart Cric. Physiol. 290, H37-H45. 
Vinod, K.Y., Hungund, B.L., 2006. Role of the endocannabinoid system in depression 
and suicide. Trends Pharmacol. Sci. 27, 539-545. 
Wang, Q., Peng, Y., Chen, S., Gou, X., Hu, B., Du, J., Lu, Y., Xiong, L., 2009. 
Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral 
ischemia through regulation of endocannabinoid system. Stroke 40, 2157-2164. 
Yokotani, K., Nishihara, M., Murakami, Y., Hasegawa, T., Okuma, Y., Osumi, Y., 1995. 
Elevation of plasma noradrenaline levels in urethane-anaesthetized rats by 
activation of central prostanoid EP3 receptors. Br. J. Pharmacol. 115, 672-676. 
27 
Yokotani, K., Wang, M., Murakami, Y., Okada, S., Hirata, M., 2000. Brain 
phospholipase A2-arachidonic acid cascade is involved in the activation of central 
sympatho-adrenomedullary outflow in rats. Eur. J. Pharmacol. 398, 341-347. 
Yokotani, K., Murakami, Y., Okada, S., Hirata, M., 2001. Role of brain arachidonic 
acid cascade on central CRF1 receptor-mediated activation of sympatho-
adrenomedullary outflow in rats. Eur. J. Pharmacol. 419, 183-189. 
   
 
 
28 
Legends to figures 
 
Fig. 1. Effect of MAFP on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines. MAFP (an inhibitor of monoacylglycerol lipase) 
(0.7 or 1.4 µmol/animal) or vehicle-1 (3 µl DMF/animal) was i.c.v. administered 30 min 
before the administration of CRF (1.5 nmol/animal, i.c.v.) or vehicle-2 (10 µl 
saline/animal, i.c.v.). (A) Increments of plasma catecholamines above the basal level at 
each time point are expressed as pg/ml. Arrows indicate the administration of 
MAFP/vehicle-1 and CRF/vehicle-2. ∆ Noradrenaline and ∆ adrenaline: increments of 
noradrenaline and adrenaline above the basal level. (B) The area under the curve (AUC) 
of the CRF-induced elevation of plasma catecholamines above the basal level is 
expressed as pg/2 h. Each point represents the mean±S.E.M. # P<0.05 versus vehicle-1- 
and vehicle-2-treated group (Bonferroni method), * P<0.05 versus vehicle-1- and CRF-
treated group (Bonferroni method). 
 
Fig. 2. Effect of AM 251 on the centrally administered CRF (0.5 nmol/animal)-induced 
elevation of plasma catecholamines. AM 251 (a selective antagonist of cannabinoid CB1 
receptors) (90 or 180 nmol/animal) or vehicle-1 (3 µl DMF/animal) was i.c.v. 
administered 30 min before the administration of CRF (0.5 nmol/animal, i.c.v.) or 
vehicle-2 (10 µl saline/animal, i.c.v.). (A) Increments of plasma catecholamines above 
the basal level. Arrows indicate the administration of AM 251/vehicle-1 and 
CRF/vehicle-2. (B) AUC of the CRF-induced elevation of plasma catecholamines above 
the basal level. The vehicle-1- and vehicle-2-treated group is the same as that in Fig. 1. 
# P<0.05 versus vehicle-1- and vehicle-2-treated group (Bonferroni method), * P<0.05 
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versus vehicle-1- and CRF-treated group (Bonferroni method). Other conditions were 
the same as those of Fig. 1. 
 
Fig. 3. Effect of AM 404 on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines. AM 404 (an uptake-inhibitor of endocannabinoid) 
(80 or 250 nmol/animal) or vehicle-1 (3 µl DMF/animal) was i.c.v. administered 60 min 
before the administration of CRF (1.5 nmol/animal, i.c.v.) or vehicle-2 (10 µl 
saline/animal, i.c.v.). (A) Increments of plasma catecholamines above the basal level. 
Arrows indicate the administration of AM 404/vehicle-1 and CRF/vehicle-2. (B) AUC 
of the CRF-induced elevation of plasma catecholamines above the basal level. # P<0.05 
versus vehicle-1- and vehicle-2-treated group (Bonferroni method), * P<0.05 versus 
vehicle-1- and CRF-treated group (Bonferroni method). Other conditions were the same 
as those of Figs. 1 and 2. 
 
Fig. 4. Effect of ACEA on the centrally administered CRF (1.5 nmol/animal)-induced 
elevation of plasma catecholamines. ACEA (a selective agonist of cannabinoid CB1 
receptors) (0.7 or 1.4 µmol/animal) or vehicle-1 (3 µl DMF/animal) was i.c.v. 
administered 30 min before the administration of CRF (1.5 nmol/animal, i.c.v.) or 
vehicle-2 (10 µl saline/animal, i.c.v.). (A) Increments of plasma catecholamines above 
the basal level. Arrows indicate the administration of ACEA/vehicle-1 and 
CRF/vehicle-2. (B) AUC of the CRF-induced elevation of plasma catecholamines above 
the basal level. # P<0.05 versus vehicle-1- and vehicle-2-treated group (Bonferroni 
method), * P<0.05 versus vehicle-1- and CRF-treated group (Bonferroni method). Other 
conditions were the same as those of Figs. 1-3. 
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